Lance David Miller

List of Publications by Citations

139 papers	11,816 citations	56 h-index	108 g-index
146 ext. papers	13,324 ext. citations	9.3 avg, IF	5.65 L-index

#	Paper	IF	Citations
139	An expression signature for p53 status in human breast cancer predicts mutation status, transcriptional effects, and patient survival. *Proceedings of the National Academy of Sciences of the United States of America*, **2005**, 102, 13550-5	11.5	999
138	A global map of p53 transcription-factor binding sites in the human genome. *Cell*, **2006**, 124, 207-19	56.2	958
137	High-fidelity mRNA amplification for gene profiling. *Nature Biotechnology*, **2000**, 18, 457-9	44.5	601
136	Gene expression profiling spares early breast cancer patients from adjuvant therapy: derived and validated in two population-based cohorts. *Breast Cancer Research*, **2005**, 7, R953-64	8.3	597
135	Genetic reclassification of histologic grade delineates new clinical subtypes of breast cancer. *Cancer Research*, **2006**, 66, 10292-301	10.1	531
134	Whole-genome cartography of estrogen receptor alpha binding sites. *PLoS Genetics*, **2007**, 3, e87	6	352
133	Papillomavirus type 16 oncogenes downregulate expression of interferon-responsive genes and upregulate proliferation-associated and NF-kappaB-responsive genes in cervical keratinocytes. *Journal of Virology*, **2001**, 75, 4283-96	6.6	300
132	Ferroportin and iron regulation in breast cancer progression and prognosis. *Science Translational Medicine*, **2010**, 2, 43ra56	17.5	296
131	Targeting aldehyde dehydrogenase cancer stem cells in ovarian cancer. *Molecular Cancer Therapeutics*, **2010**, 9, 3186-99	6.1	284
130	Conservation of gene expression signatures between zebrafish and human liver tumors and tumor progression. *Nature Biotechnology*, **2006**, 24, 73-5	44.5	249
129	Transcriptome analysis of zebrafish embryogenesis using microarrays. *PLoS Genetics*, **2005**, 1, 260-76	6	244
128	Discovery of estrogen receptor alpha target genes and response elements in breast tumor cells. *Genome Biology*, **2004**, 5, R66	18.3	213
127	Intrinsic molecular signature of breast cancer in a population-based cohort of 412 patients. *Breast Cancer Research*, **2006**, 8, R34	8.3	188
126	Prospective molecular profiling of melanoma metastases suggests classifiers of immune responsiveness. *Cancer Research*, **2002**, 62, 3581-6	10.1	179
125	Iron addiction: a novel therapeutic target in ovarian cancer. *Oncogene*, **2017**, 36, 4089-4099	9.2	169
124	Sal-like protein 4 (SALL4), a stem cell biomarker in liver cancers. *Hepatology*, **2013**, 57, 1469-83	11.2	153
123	Molecular changes from dysplastic nodule to hepatocellular carcinoma through gene expression profiling. *Hepatology*, **2005**, 42, 809-18	11.2	153

122	An iron regulatory gene signature predicts outcome in breast cancer. *Cancer Research*, **2011**, 71, 6728-37	10.1	141
121	Identification of cell cycle-regulated genes in fission yeast. *Molecular Biology of the Cell*, **2005**, 16, 1026-42	35	141
120	Identifying baseline immune-related biomarkers to predict clinical outcome of immunotherapy **2017**, 5, 44		139
119	Gene expression preferentially regulated by tamoxifen in breast cancer cells and correlations with clinical outcome. *Cancer Research*, **2006**, 66, 7334-40	10.1	133
118	Interactions between immunity, proliferation and molecular subtype in breast cancer prognosis. *Genome Biology*, **2013**, 14, R34	18.3	131
117	CDKN1C (p57) is a direct target of EZH2 and suppressed by multiple epigenetic mechanisms in breast cancer cells. *PLoS ONE*, **2009**, 4, e5011	3.7	131
116	Tumor mutational burden is a determinant of immune-mediated survival in breast cancer. *OncoImmunology*, **2018**, 7, e1490854	7.2	129
115	Gene-expression profiling of the response of peripheral blood mononuclear cells and melanoma metastases to systemic IL-2 administration. *Genome Biology*, **2002**, 3, RESEARCH0035	18.3	129
114	Optimal gene expression analysis by microarrays. *Cancer Cell*, **2002**, 2, 353-61	24.3	128
113	Safety and tolerability of the first-in-class agent CPI-613 in combination with modified FOLFIRINOX in patients with metastatic pancreatic cancer: a single-centre, open-label, dose-escalation, phase 1 trial. *Lancet Oncology, The*, **2017**, 18, 770-778	21.7	120
112	Positive cross-talk between estrogen receptor and NF-kappaB in breast cancer. *Cancer Research*, **2009**, 69, 8918-25	10.1	112
111	Laboratory-acquired severe acute respiratory syndrome. *New England Journal of Medicine*, **2004**, 350, 1740-5	59.2	107
110	A precisely regulated gene expression cassette potently modulates metastasis and survival in multiple solid cancers. *PLoS Genetics*, **2008**, 4, e1000129	6	106
109	THY1 is a candidate tumour suppressor gene with decreased expression in metastatic nasopharyngeal carcinoma. *Oncogene*, **2005**, 24, 6525-32	9.2	106
108	Concordance among gene expression-based predictors for ER-positive breast cancer treated with adjuvant tamoxifen. *Annals of Oncology*, **2012**, 23, 2866-2873	10.3	103
107	Cyclin E2 overexpression is associated with endocrine resistance but not insensitivity to CDK2 inhibition in human breast cancer cells. *Molecular Cancer Therapeutics*, **2012**, 11, 1488-99	6.1	101
106	DEAD-box helicase DP103 defines metastatic potential of human breast cancers. *Journal of Clinical Investigation*, **2014**, 124, 3807-24	15.9	98
105	Hepcidin regulation in prostate and its disruption in prostate cancer. *Cancer Research*, **2015**, 75, 2254-63	10.1	97

104	RCP is a human breast cancer-promoting gene with Ras-activating function. *Journal of Clinical Investigation*, **2009**, 119, 2171-83	15.9	89
103	Tracking the evolution of the SARS coronavirus using high-throughput, high-density resequencing arrays. *Genome Research*, **2004**, 14, 398-405	9.7	88
102	Identification of genetic determinants of breast cancer immune phenotypes by integrative genome-scale analysis. *OncoImmunology*, **2017**, 6, e1253654	7.2	87
101	Inhibitory effects of estrogen receptor beta on specific hormone-responsive gene expression and association with disease outcome in primary breast cancer. *Breast Cancer Research*, **2007**, 9, R25	8.3	82
100	Neurotensin receptor 1 determines the outcome of non-small cell lung cancer. *Clinical Cancer Research*, **2010**, 16, 4401-10	12.9	80
99	YB-1, the E2F pathway, and regulation of tumor cell growth. *Journal of the National Cancer Institute*, **2012**, 104, 133-46	9.7	79
98	CT-X antigen expression in human breast cancer. *Proceedings of the National Academy of Sciences of the United States of America*, **2009**, 106, 13493-8	11.5	78
97	Silencing of Wnt signaling and activation of multiple metabolic pathways in response to thyroid hormone-stimulated cell proliferation. *Molecular and Cellular Biology*, **2001**, 21, 6626-39	4.8	78
96	TMIC-36. ALDH1A2 AS A NOVEL PUTATIVE MARKER OF MACROPHAGE DIFFERENTIATION IN GBM. *Neuro-Oncology*, **2019**, 21, vi255-vi255	1	78
95	IRP2 regulates breast tumor growth. *Cancer Research*, **2014**, 74, 497-507	10.1	77
94	Renal-Risk Variants Induce Mitochondrial Dysfunction. *Journal of the American Society of Nephrology: JASN*, **2017**, 28, 1093-1105	12.7	75
93	JMJD6 is a driver of cellular proliferation and motility and a marker of poor prognosis in breast cancer. *Breast Cancer Research*, **2012**, 14, R85	8.3	71
92	Yin Yang 1 contains G-quadruplex structures in its promoter and 5SUTR and its expression is modulated by G4 resolvase 1. *Nucleic Acids Research*, **2012**, 40, 1033-49	20.1	69
91	Transcriptome kinetics of arsenic-induced adaptive response in zebrafish liver. *Physiological Genomics*, **2006**, 27, 351-61	3.6	69
90	Yin Yang 1 plays an essential role in breast cancer and negatively regulates p27. *American Journal of Pathology*, **2012**, 180, 2120-33	5.8	65
89	Dissecting intratumoral myeloid cell plasticity by single cell RNA-seq. *Cancer Medicine*, **2019**, 8, 3072-3085	4.8	61
88	Identification of white spot syndrome virus latency-related genes in specific-pathogen-free shrimps by use of a microarray. *Journal of Virology*, **2003**, 77, 10162-7	6.6	61
87	Immunogenic Subtypes of Breast Cancer Delineated by Gene Classifiers of Immune Responsiveness. *Cancer Immunology Research*, **2016**, 4, 600-10	12.5	61

86	A phase I study of the first-in-class antimitochondrial metabolism agent, CPI-613, in patients with advanced hematologic malignancies. *Clinical Cancer Research*, **2014**, 20, 5255-64	12.9	60
85	Genomic profiles specific to patient ethnicity in lung adenocarcinoma. *Clinical Cancer Research*, **2011**, 17, 3542-50	12.9	60
84	Prognostic and predictive immune gene signatures in breast cancer. *Current Opinion in Oncology*, **2015**, 27, 433-44	4.2	57
83	HOXA1-stimulated oncogenicity is mediated by selective upregulation of components of the p44/42 MAP kinase pathway in human mammary carcinoma cells. *Oncogene*, **2007**, 26, 3998-4008	9.2	51
82	Conservation of immune gene signatures in solid tumors and prognostic implications. *BMC Cancer*, **2016**, 16, 911	4.8	50
81	Functional analysis of a cell cycle-associated, tumor-suppressive gene, protein tyrosine phosphatase receptor type G, in nasopharyngeal carcinoma. *Cancer Research*, **2008**, 68, 8137-45	10.1	49
80	Trefoil factor 3 is oncogenic and mediates anti-estrogen resistance in human mammary carcinoma. *Neoplasia*, **2010**, 12, 1041-53	6.4	45
79	The regulation of SOX7 and its tumor suppressive role in breast cancer. *American Journal of Pathology*, **2013**, 183, 1645-1653	5.8	44
78	Prediction of clinical outcome in multiple lung cancer cohorts by integrative genomics: implications for chemotherapy selection. *Cancer Research*, **2009**, 69, 1055-62	10.1	44
77	Optimization and clinical validation of a pathogen detection microarray. *Genome Biology*, **2007**, 8, R93	18.3	44
76	Gene expression profiling to identify oncogenic determinants of autocrine human growth hormone in human mammary carcinoma. *Journal of Biological Chemistry*, **2005**, 280, 23987-4003	5.4	43
75	Early and Locally Advanced Metaplastic Breast Cancer: Presentation and Survival by Receptor Status in Surveillance, Epidemiology, and End Results (SEER) 2010-2014. *Oncologist*, **2018**, 23, 481-488	5.7	42
74	RAS Mutations and Oncogenesis: Not all RAS Mutations are Created Equally. *Frontiers in Genetics*, **2011**, 2, 100	4.5	42
73	In the pursuit of complexity: systems medicine in cancer biology. *Cancer Cell*, **2006**, 9, 245-7	24.3	42
72	Combined genomic and phenotype screening reveals secretory factor SPINK1 as an invasion and survival factor associated with patient prognosis in breast cancer. *EMBO Molecular Medicine*, **2011**, 3, 451-64	12	41
71	Correlation test to assess low-level processing of high-density oligonucleotide microarray data. *BMC Bioinformatics*, **2005**, 6, 80	3.6	41
70	A Phase I Study of CPI-613 in Combination with High-Dose Cytarabine and Mitoxantrone for Relapsed or Refractory Acute Myeloid Leukemia. *Clinical Cancer Research*, **2018**, 24, 2060-2073	12.9	40
69	Hormone-replacement therapy influences gene expression profiles and is associated with breast-cancer prognosis: a cohort study. *BMC Medicine*, **2006**, 4, 16	11.4	40

68	Model of Patient-Specific Immune-Enhanced Organoids for Immunotherapy Screening: Feasibility Study. *Annals of Surgical Oncology*, **2020**, 27, 1956-1967	3.1	40
67	Artemin is estrogen regulated and mediates antiestrogen resistance in mammary carcinoma. *Oncogene*, **2010**, 29, 3228-40	9.2	39
66	Dual roles for immune metagenes in breast cancer prognosis and therapy prediction. *Genome Medicine*, **2014**, 6, 80	14.4	37
65	A modular analysis of breast cancer reveals a novel low-grade molecular signature in estrogen receptor-positive tumors. *Clinical Cancer Research*, **2006**, 12, 3288-96	12.9	37
64	ERR□s a Marker of Tamoxifen Response and Survival in Triple-Negative Breast Cancer. *Clinical Cancer Research*, **2016**, 22, 1421-31	12.9	36
63	Strategies to defeat ketamine-induced neonatal brain injury. *Neuroscience*, **2012**, 210, 384-92	3.9	36
62	EGFR and HER2 signaling in breast cancer brain metastasis. *Frontiers in Bioscience - Elite*, **2016**, 8, 245-63	1.6	36
61	Disentangling the relationship between tumor genetic programs and immune responsiveness. *Current Opinion in Immunology*, **2016**, 39, 150-8	7.8	34
60	Expression genomics in breast cancer research: microarrays at the crossroads of biology and medicine. *Breast Cancer Research*, **2007**, 9, 206	8.3	33
59	Exosomal microRNA profiling to identify hypoxia-related biomarkers in prostate cancer. *Oncotarget* , **2018**, 9, 13894-13910	3.3	33
58	SOSTDC1 differentially modulates Smad and beta-catenin activation and is down-regulated in breast cancer. *Breast Cancer Research and Treatment*, **2011**, 129, 737-46	4.4	32
57	Establishment and metabolic analysis of a model microbial community for understanding trophic and electron accepting interactions of subsurface anaerobic environments. *BMC Microbiology*, **2010** , 10, 149	4.5	31
56	Transcription patterning of uncoupled proliferation and differentiation in myelodysplastic bone marrow with erythroid-focused arrays. *Blood*, **2001**, 98, 1914-21	2.2	31
55	Prognostic value of the hDMP1-ARF-Hdm2-p53 pathway in breast cancer. *Oncogene*, **2013**, 32, 4120-9	9.2	30
54	Multi-tissue gene-expression analysis in a mouse model of thyroid hormone resistance. *Genome Biology*, **2004**, 5, R31	18.3	29
53	Prognostic Molecular Subtypes of Low-Grade Cancer of the Appendix. *Journal of the American College of Surgeons*, **2016**, 222, 493-503	4.4	28
52	Frequent decreased expression of candidate tumor suppressor gene, DEC1, and its anchorage-independent growth properties and impact on global gene expression in esophageal carcinoma. *International Journal of Cancer*, **2008**, 122, 587-94	7.5	27
51	Pleural Effusion Aspirate for use in 3D Lung Cancer Modeling and Chemotherapy Screening. *ACS Biomaterials Science and Engineering*, **2019**, 5, 1937-1943	5.5	25

50	Comparison of clinical outcomes and genomic characteristics of single focus and multifocal glioblastoma. *Journal of Neuro-Oncology*, **2014**, 119, 429-35	4.8	25
49	Addressing the Adult Soft Tissue Sarcoma Microenvironment with Intratumoral Immunotherapy. *Sarcoma*, **2018**, 2018, 9305294	3.1	24
48	Oncogenic states dictate the prognostic and predictive connotations of intratumoral immune response **2020**, 8,		23
47	CD38 Inhibits Prostate Cancer Metabolism and Proliferation by Reducing Cellular NAD Pools. *Molecular Cancer Research*, **2018**, 16, 1687-1700	6.6	23
46	Monochromosome transfer and microarray analysis identify a critical tumor-suppressive region mapping to chromosome 13q14 and THSD1 in esophageal carcinoma. *Molecular Cancer Research*, **2008**, 6, 592-603	6.6	23
45	Yin Yang 1 promotes mTORC2-mediated AKT phosphorylation. *Journal of Molecular Cell Biology*, **2016**, 8, 232-43	6.3	21
44	Mutational Landscapes of Smoking-Related Cancers in Caucasians and African Americans: Precision Oncology Perspectives at Wake Forest Baptist Comprehensive Cancer Center. *Theranostics*, **2017**, 7, 2914-2923	12.1	20
43	Activin A Promotes Regulatory T-cell-Mediated Immunosuppression in Irradiated Breast Cancer. *Cancer Immunology Research*, **2021**, 9, 89-102	12.5	20
42	Identifying gene expression changes in breast cancer that distinguish early and late relapse among uncured patients. *Bioinformatics*, **2006**, 22, 1477-85	7.2	19
41	Kidney-Risk Variants Induce Mitochondrial Fission. *Kidney International Reports*, **2020**, 5, 891-904	4.1	14
40	scLM: Automatic Detection of Consensus Gene Clusters Across Multiple Single-cell Datasets. *Genomics, Proteomics and Bioinformatics*, **2021**, 19, 330-341	6.5	14
39	Multi-Omics Analysis of Brain Metastasis Outcomes Following Craniotomy. *Frontiers in Oncology*, **2020**, 10, 615472	5.3	13
38	The nuclear structural protein NuMA is a negative regulator of 53BP1 in DNA double-strand break repair. *Nucleic Acids Research*, **2019**, 47, 2703-2715	20.1	13
37	Systems biology approach to studying proliferation-dependent prognostic subnetworks in breast cancer. *Scientific Reports*, **2015**, 5, 12981	4.9	11
36	Gene profile and response to treatment. *Annals of Oncology*, **2005**, 16 Suppl 2, ii195-202	10.3	11
35	A collection of annotated and harmonized human breast cancer transcriptome datasets, including immunologic classification. *F1000Research*, **2017**, 6, 296	3.6	11
34	BEARR: Batch Extraction and Analysis of cis-Regulatory Regions. *Nucleic Acids Research*, **2004**, 32, W257-60	20.1	10
33	A search for candidate genes for lipodystrophy, obesity and diabetes via gene expression analysis of A-ZIP/F-1 mice. *Genomics*, **2003**, 81, 378-90	4.3	10

32	A collection of annotated and harmonized human breast cancer transcriptome datasets, including immunologic classification. *F1000Research*, **2017**, 6, 296	3.6	10
31	Effects of Pubertal Exposure to Dietary Soy on Estrogen Receptor Activity in the Breast of Cynomolgus Macaques. *Cancer Prevention Research*, **2016**, 9, 385-95	3.2	9
30	Intrapleural nano-immunotherapy promotes innate and adaptive immune responses to enhance anti-PD-L1 therapy for malignant pleural effusion.. *Nature Nanotechnology*, **2021**,	28.7	8
29	Genomic predictors of patterns of progression in glioblastoma and possible influences on radiation field design. *Journal of Neuro-Oncology*, **2015**, 124, 447-53	4.8	7
28	Organoid Platform in Preclinical Investigation of Personalized Immunotherapy Efficacy in Appendiceal Cancer: Feasibility Study. *Clinical Cancer Research*, **2021**, 27, 5141-5150	12.9	7
27	Dysregulated Pyrimidine Biosynthesis Contributes to 5-FU Resistance in SCLC Patient-Derived Organoids but Response to a Novel Polymeric Fluoropyrimidine, CF10. *Cancers*, **2020**, 12,	6.6	6
26	Glioblastoma radiomics: can genomic and molecular characteristics correlate with imaging response patterns?. *Neuroradiology*, **2018**, 60, 1043-1051	3.2	6
25	LOMA: a fast method to generate efficient tagged-random primers despite amplification bias of random PCR on pathogens. *BMC Bioinformatics*, **2008**, 9, 368	3.6	6
24	Prognostic Molecular Classification of Appendiceal Mucinous Neoplasms Treated with Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy. *Annals of Surgical Oncology*, **2020**, 27, 1439-1447	3.1	5
23	Identification of CD37, cystatin A, and IL-23A gene expression in association with brain metastasis: analysis of a prospective trial. *International Journal of Biological Markers*, **2019**, 34, 90-97	2.8	4
22	Toward the identification of genetic determinants of breast cancer immune responsiveness **2015**, 3, P1		4
21	Clinical Implications of Genetic Signatures in Appendiceal Cancer Patients with Incomplete Cytoreduction/HIPEC. *Annals of Surgical Oncology*, **2020**, 27, 5016-5023	3.1	4
20	Feasibility of lung cancer RNA acquisition from a single transbronchial or transthoracic needle pass (FASTT trial). *Lung Cancer*, **2019**, 127, 6-11	5.9	4
19	Identifying driver genes in cancer by triangulating gene expression, gene location, and survival data. *Cancer Informatics*, **2014**, 13, 35-48	2.4	3
18	GENOME-WIDE CDNA OLIGO PROBE DESIGN AND ITS APPLICATIONS IN SCHIZOSACCHAROMYCES POMBE **2004**, 347-358		3
17	Transcriptomic Features of T Cell-Barren Tumors Are Conserved Across Diverse Tumor Types. *Frontiers in Immunology*, **2020**, 11, 57	8.4	2
16	and Are Novel Mediators of Resistance to Oncolytic Vesicular Stomatitis Virus in Prostate Cancer Cells. *Molecular Therapy - Oncolytics*, **2020**, 17, 496-507	6.4	2
15	Immune gene signatures and tumor intrinsic markers delineate novel immunogenic subtypes of breast cancer **2014**, 2,		2

14	Multimodal Assessment of Estrogen Receptor mRNA Profiles to Quantify Estrogen Pathway Activity in Breast Tumors. *Clinical Breast Cancer*, **2017**, 17, 139-153	3	2
13	TCA Cycle Inhibition By Cpi-613 Increases Sensitivity to Chemotherapy in Older and Poor Risk Acute Myeloid Leukemia (AML). *Blood*, **2016**, 128, 4062-4062	2.2	2
12	scLM: automatic detection of consensus gene clusters across multiple single-cell datasets		2
11	Conditional activation of immune-related signatures and prognostic significance: a pan-cancer analysis		2
10	ASO Author Reflections: Molecular Profiling Can Provide Personalized Clinical Guidance in the Management of Peritoneal Malignancies. *Annals of Surgical Oncology*, **2020**, 27, 5024-5025	3.1	2
9	Epigenetic and Posttranscriptional Modulation of SOS1 Can Promote Breast Cancer Metastasis through Obesity-Activated c-Met Signaling in African-American Women. *Cancer Research*, **2021**, 81, 3008-3021	10.1	2
8	CD138 plasma cells may predict brain metastasis recurrence following resection and stereotactic radiosurgery. *Scientific Reports*, **2019**, 9, 14385	4.9	1
7	Expression profiling and breast cancer biology. *Breast Disease*, **2004**, 19, 29-34	1.6	1
6	206 An immune-competent tumor organoid platform to test novel immune checkpoint combinations targeting the receptor CD47 in triple negative breast cancer **2020**, 8, A222-A222		1
5	Weighted Top Score Pair Method for Gene Selection and Classification. *Lecture Notes in Computer Science*, **2008**, 323-333	0.9	1
4	Comprehensive and Computable Molecular Diagnostic Panel (C2Dx) From Small Volume Specimens for Precision Oncology: Molecular Subtyping of Non-Small Cell Lung Cancer From Fine Needle Aspirates. *Frontiers in Oncology*, **2021**, 11, 584896	5.3	0
3	Phase II trial of cytarabine and mitoxantrone with devimistat in acute myeloid leukemia.. *Nature Communications*, **2022**, 13, 1673	17.4	0
2	Circulating Immune Bioenergetic, Metabolic, and Genetic Signatures Predict Melanoma PatientsS Response to Anti-PD-1 Immune Checkpoint Blockade.. *Clinical Cancer Research*, **2022**, 28, 1192-1202	12.9	0
1	Bulk and Single-Cell Profiling of Breast Tumors Identifies TREM-1 as a Dominant Immune Suppressive Marker Associated With Poor Outcomes.. *Frontiers in Oncology*, **2021**, 11, 734959	5.3	0